• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长期疫苗诱导的对雪貂模型中 H5N1 流感病毒的异源保护作用。

Long-term vaccine-induced heterologous protection against H5N1 influenza viruses in the ferret model.

机构信息

Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, USA.

出版信息

Influenza Other Respir Viruses. 2013 Jul;7(4):506-12. doi: 10.1111/j.1750-2659.2012.00423.x. Epub 2012 Aug 16.

DOI:10.1111/j.1750-2659.2012.00423.x
PMID:22897930
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3505228/
Abstract

BACKGROUND

Highly pathogenic H5N1 influenza viruses reemerged in humans in 2003 and have caused fatal human infections in Asia and Africa as well as ongoing outbreaks in poultry. These viruses have evolved substantially and are now so antigenically varied that a single vaccine antigen may not protect against all circulating strains. Nevertheless, studies have shown that substantial cross-reactivity can be achieved with H5N1 vaccines. These studies have not, however, addressed the issue of duration of such cross-reactive protection.

OBJECTIVES

To directly address this using the ferret model, we used two recommended World Health Organization H5N1 vaccine seed strains - A/Vietnam/1203/04 (clade 1) and A/duck/Hunan/795/02 (clade 2.1) - seven single, double, or triple mutant viruses based on A/Vietnam/1203/04, and the ancestral viruses A and D, selected from sequences at nodes of the hemagglutinin and neuraminidase gene phylogenies to represent antigenically diverse progeny H5N1 subclades as vaccine antigens.

RESULTS

All inactivated whole-virus vaccines provided full protection against morbidity and mortality in ferrets challenged with the highly pathogenic H5N1 strain A/Vietnam/1203/04 5 months and 1 year after immunization.

CONCLUSION

If an H5N1 pandemic was to arise, and with the hypothesis that one can extrapolate the results from three doses of a whole-virion vaccine in ferrets to the available split vaccines for use in humans, the population could be efficiently immunized with currently available H5N1 vaccines, while the homologous vaccine is under production.

摘要

背景

高致病性 H5N1 流感病毒于 2003 年在人类中重新出现,并在亚洲和非洲导致了致命的人类感染,以及家禽中的持续爆发。这些病毒已经发生了实质性的进化,现在抗原性差异很大,单一疫苗抗原可能无法预防所有流行株。然而,研究表明,H5N1 疫苗可以实现实质性的交叉反应。然而,这些研究并未解决这种交叉反应性保护的持续时间问题。

目的

我们使用两种推荐的世界卫生组织 H5N1 疫苗种株——A/Vietnam/1203/04(谱系 1)和 A/duck/Hunan/795/02(谱系 2.1)——以及基于 A/Vietnam/1203/04 的七种单一、双或三重突变病毒,以及来自血凝素和神经氨酸酶基因系统发育树节点的祖先病毒 A 和 D,选择了代表抗原多样化后代 H5N1 亚谱系的疫苗抗原,直接在雪貂模型中解决这个问题。

结果

所有灭活全病毒疫苗都为雪貂提供了完全保护,使其免受高致病性 H5N1 株 A/Vietnam/1203/04 的发病率和死亡率的影响,免疫后 5 个月和 1 年进行挑战。

结论

如果 H5N1 大流行出现,并且假设可以从三剂全病毒疫苗在雪貂中的结果推断出可用于人类的现有分拆疫苗,那么可以利用现有的 H5N1 疫苗有效地对人群进行免疫,而同源疫苗正在生产中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1266/4941745/0fa2807cabd5/IRV-7-506-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1266/4941745/0fa2807cabd5/IRV-7-506-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1266/4941745/0fa2807cabd5/IRV-7-506-g001.jpg

相似文献

1
Long-term vaccine-induced heterologous protection against H5N1 influenza viruses in the ferret model.长期疫苗诱导的对雪貂模型中 H5N1 流感病毒的异源保护作用。
Influenza Other Respir Viruses. 2013 Jul;7(4):506-12. doi: 10.1111/j.1750-2659.2012.00423.x. Epub 2012 Aug 16.
2
Single- and multiple-clade influenza A H5N1 vaccines induce cross protection in ferrets.单分支和多分支甲型H5N1流感疫苗可在雪貂中诱导交叉保护。
Vaccine. 2009 Jun 24;27(31):4187-95. doi: 10.1016/j.vaccine.2009.04.050. Epub 2009 May 9.
3
Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.针对快速进化的H5亚型病毒开发具有分支特异性和广泛反应性的减毒活流感病毒疫苗。
J Virol. 2017 Jul 12;91(15). doi: 10.1128/JVI.00547-17. Print 2017 Aug 1.
4
Evaluation of heterosubtypic cross-protection against highly pathogenic H5N1 by active infection with human seasonal influenza A virus or trivalent inactivated vaccine immunization in ferret models.评估通过主动感染人季节性甲型流感病毒或三价灭活疫苗免疫在雪貂模型中对高致病性 H5N1 的异源交叉保护作用。
J Gen Virol. 2014 Apr;95(Pt 4):793-798. doi: 10.1099/vir.0.058636-0. Epub 2014 Jan 13.
5
Evaluation of the efficacy of a pre-pandemic H5N1 vaccine (MG1109) in mouse and ferret models.评估一种大流行前 H5N1 疫苗(MG1109)在小鼠和雪貂模型中的功效。
J Microbiol. 2012 Jun;50(3):478-88. doi: 10.1007/s12275-012-1573-z. Epub 2012 Jun 30.
6
Neuraminidase-inhibiting antibody is a correlate of cross-protection against lethal H5N1 influenza virus in ferrets immunized with seasonal influenza vaccine.神经氨酸酶抑制抗体是用季节性流感疫苗免疫的雪貂对致死性 H5N1 流感病毒产生交叉保护作用的相关因素。
J Virol. 2013 Mar;87(6):3053-61. doi: 10.1128/JVI.02434-12. Epub 2013 Jan 2.
7
M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.新型活流感疫苗M2SR可保护小鼠和雪貂免受高致病性禽流感的侵害。
Vaccine. 2017 Jul 24;35(33):4177-4183. doi: 10.1016/j.vaccine.2017.06.039. Epub 2017 Jun 28.
8
Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.灭活及佐剂全病毒 2.3.4 分支 H5N1 大流行前流感疫苗在小鼠中对异源高致病性 H5N1 禽流感病毒具有广泛的保护效力。
Vaccine. 2011 Oct 26;29(46):8330-7. doi: 10.1016/j.vaccine.2011.08.091. Epub 2011 Sep 10.
9
Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and cross-protective immunity in ferrets.针对大流行 H5N1 流感病毒的细菌 HA1 疫苗:在雪貂中具有寡聚化、血凝和交叉保护免疫的证据。
J Virol. 2011 Feb;85(3):1246-56. doi: 10.1128/JVI.02107-10. Epub 2010 Nov 17.
10
Stockpiled pre-pandemic H5N1 influenza virus vaccines with AS03 adjuvant provide cross-protection from H5N2 clade 2.3.4.4 virus challenge in ferrets.储备的大流行前含AS03佐剂的H5N1流感病毒疫苗可在雪貂中对H5N2 2.3.4.4分支病毒攻击提供交叉保护。
Virology. 2017 Aug;508:164-169. doi: 10.1016/j.virol.2017.05.010. Epub 2017 May 26.

引用本文的文献

1
Pandemic preparedness through vaccine development for avian influenza viruses.通过开发针对禽流感病毒的疫苗做好大流行的准备。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2347019. doi: 10.1080/21645515.2024.2347019. Epub 2024 May 28.
2
The Quest for a Truly Universal Influenza Vaccine.追寻真正通用的流感疫苗
Front Cell Infect Microbiol. 2019 Oct 10;9:344. doi: 10.3389/fcimb.2019.00344. eCollection 2019.
3
Avian Influenza A Virus Pandemic Preparedness and Vaccine Development.甲型禽流感病毒大流行防范与疫苗研发

本文引用的文献

1
Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses for development of candidate vaccines viruses for pandemic preparedness - February 2011.用于大流行防范的甲型流感病毒A(H5N1)和A(H9N2)候选疫苗病毒研发的抗原及基因特征——2011年2月
Wkly Epidemiol Rec. 2011 Mar 11;86(11):93-100.
2
Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus.抗核蛋白 IgG 对流感病毒异源免疫的贡献。
J Immunol. 2011 Apr 1;186(7):4331-9. doi: 10.4049/jimmunol.1003057. Epub 2011 Feb 25.
3
Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets.
Vaccines (Basel). 2018 Jul 25;6(3):46. doi: 10.3390/vaccines6030046.
4
Post-exposure treatment with whole inactivated H5N1 avian influenza virus protects against lethal homologous virus infection in mice.全灭活 H5N1 禽流感病毒的暴露后治疗可预防小鼠感染同源致命病毒。
Sci Rep. 2016 Jul 12;6:29433. doi: 10.1038/srep29433.
5
Quantitative measurement of influenza virus replication using consecutive bronchoalveolar lavage in the lower respiratory tract of a ferret model.利用雪貂模型下呼吸道连续支气管肺泡灌洗对流感病毒复制进行定量测量。
J Vet Sci. 2014;15(3):439-42. doi: 10.4142/jvs.2014.15.3.439. Epub 2014 Apr 2.
经 AS03A 佐剂加强的 H5N1 裂解疫苗一剂或两剂接种后诱导的保护性免疫应答的持久性。
Vaccine. 2011 Mar 3;29(11):2092-9. doi: 10.1016/j.vaccine.2010.12.128. Epub 2011 Jan 13.
4
Influenza vaccine immunology.流感疫苗免疫学。
Immunol Rev. 2011 Jan;239(1):167-77. doi: 10.1111/j.1600-065X.2010.00974.x.
5
Feasibility of reconstructed ancestral H5N1 influenza viruses for cross-clade protective vaccine development.重建的始祖 H5N1 流感病毒用于跨谱系保护疫苗开发的可行性。
Proc Natl Acad Sci U S A. 2011 Jan 4;108(1):349-54. doi: 10.1073/pnas.1012457108. Epub 2010 Dec 20.
6
Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective.大流行性流感 A(H1N1)的教训:基于研究的疫苗产业的观点。
Vaccine. 2011 Feb 1;29(6):1135-8. doi: 10.1016/j.vaccine.2010.11.042. Epub 2010 Nov 27.
7
Evaluation of the cellular immune responses induced by a non-adjuvanted inactivated whole virus A/H5N1/VN/1203 pandemic influenza vaccine in humans.评估无佐剂灭活全病毒 A/H5N1/VN/1203 大流行流感疫苗在人体中诱导的细胞免疫应答。
Vaccine. 2010 Dec 16;29(2):166-73. doi: 10.1016/j.vaccine.2010.10.065. Epub 2010 Nov 4.
8
Potent vesicular stomatitis virus-based avian influenza vaccines provide long-term sterilizing immunity against heterologous challenge.基于强感染力水泡性口炎病毒的禽流感疫苗可提供针对异源挑战的长期有效免疫性。
J Virol. 2010 May;84(9):4611-8. doi: 10.1128/JVI.02637-09. Epub 2010 Feb 24.
9
Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.AS03 佐剂甲型 H5N1 流感疫苗加强免疫可改善异源加强免疫后的免疫应答动力学、幅度和持久性:一项双盲随机对照初级研究的开放性非随机扩展。
Vaccine. 2010 Jan 8;28(3):849-57. doi: 10.1016/j.vaccine.2009.10.017. Epub 2009 Oct 14.
10
Pandemic influenza as a current threat.大流行性流感作为当前的一种威胁。
Curr Top Microbiol Immunol. 2009;333:3-24. doi: 10.1007/978-3-540-92165-3_1.